Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.

The recent first global approval of tivozanib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Tivozanib (Fotiva®): First Global Approval – selective agent for optimal VEGF blockade in adults with renal cell carcinoma.”